Four Chinese biotech companies reach in- and out-licensing deals covering antibody drug conjugates, small molecules and vaccines as they continue to pursue and develop innovation.

Beijing expands mass testing to more areas and Shanghai’s case fatally rate raises questions amid China deals with the worst outbreak in two years.

Regeneron hopes to bolster its immuno-oncology pipeline with the acquisition of Checkmate, which joins a spate of similar deals suggesting renewed interest in biotech investment despite an industry-wide slowdown.

Halozyme will pay $960m to acquire Antares, gaining an auto-injector drug delivery platform, which the company said has broad licensing potential, as well as a commercial portfolio.